Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Carboplatin for First-line Ovarian Cancer
NCT03818282Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 2019
- Primary completion
- Jun 2023
- Sponsor
- Huazhong University of Science and Technology
- Modality
- Small Molecules
- Drugs
- paclitaxel
- Conditions
- ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Huazhong University of Science and Technology. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental Arm
Nab-paclitaxel + Carboplatin
03
Who it enrols
Patients with histologically confirmed stage IC-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer who underwent ideal tumor reduction within 6 weeks prior to enrollment.
04
Endpoints
Primary
Progression-Free Survival
Beyond the preview
Go deeper on NCT03818282.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818282.